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Abstract
Background: With the increasing interest in vaccines to interrupt malaria transmission, there is a demand for
harmonization of current methods to assess Plasmodium transmission in laboratory settings. Potential vaccine
candidates are currently tested in the standard membrane feeding assay (SMFA) that commonly relies on
Anopheles stephensi mosquitoes. Other mosquito species including Anopheles gambiae are the dominant
malaria vectors for Plasmodium falciparum in sub-Saharan Africa.
Methods: Using human serum and monoclonal pre-fertilization (anti-Pfs48/45) and post-fertilization (anti-Pfs25)
antibodies known to effectively inhibit sporogony, we directly compared SMFA based estimates of transmission-
reducing activity (TRA) for An. stephensi and An. gambiae mosquitoes.
Results: In the absence of transmission-reducing antibodies, average numbers of oocysts were similar between
An. gambiae and An. stephensi. Antibody-mediated TRA was strongly correlated between both mosquito species,
and absolute TRA estimates for pre-fertilisation monoclonal antibodies (mAb) showed no significant difference
between the two species. TRA estimates for IgG of naturally exposed individuals and partially effective concentrations
of anti-Pfs25 mAb were higher for An. stephensi than for An. gambiae.
Conclusion: Our findings support the use of An. stephensi in the SMFA for target prioritization. As a vaccine moves
through product development, better estimates of TRA and transmission-blocking activity (TBA) may need to be
obtained in epidemiologically relevant parasite-species combination.
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Background
Recent declines in Plasmodium falciparum malaria trans-
mission intensity in several African settings, associated with
the wide-scale deployment of efficacious vector control and
artemisinin combination therapy [1], have contributed to a
renewed interest in the elimination of malaria. Further scal-
ing up of control efforts with currently available tools is un-
likely to achieve this goal in most African settings [2] and
interventions that specifically target malaria transmission
are considered highly desirable to accelerate elimination ef-
forts [3]. Vaccines that interrupt malaria transmission
(VIMT) are high on the priority list for malaria elimination
[4]. These include classical transmission-blocking vaccines
that target sexual, sporogonic, or mosquito stages of the
parasite (SSM-VIMT) and interfere with parasite transmis-
sion in the vector host. Recent success in obtaining prop-
erly folded vaccine candidates that elicit functional
transmission-blocking immunity in animal models have
paved the way for clinical development of lead SSM-VIMT
candidates (reviewed in [5–7]). For P. falciparum, these
candidates include vaccines based on parasite antigens
Pfs230, Pfs48/45, Pfs25 and mosquito antigen AnAPN1
[5] acting on different life-stages during sporogonic
development.
Malaria transmission starts with the ingestion of male
and female gametocytes by blood-feeding anophelines.
Upon ingestion, gametocytes quickly differentiate into
male microgametes and female macrogametes that fuse
to form zygotes. Within 18–24 h this zygote turns into a
motile ookinete which penetrates the mosquito midgut
epithelium and differentiates into an oocyst [8]. Over the
next two weeks sporozoites do develop inside the oocyst,
eventually bursting the oocyst capsule before migrating
to and invading the salivary glands, rendering the mos-
quito infective to humans. Both vaccine-induced and
naturally acquired antibodies against Pfs230 and Pfs48/
45 can prevent fertilization and thus zygote formation
[9–12]. Antibodies against Pfs25 prevent ookinete pene-
tration of the mosquito midgut [13, 14] while antibodies
against AnAPN1 also block ookinete penetration by pre-
venting the parasite interacting with mosquito midgut li-
gands [15, 16].
Clinical development of SSM-VIMTs has been primar-
ily guided by assessments of TRA in the SMFA that uti-
lizes the African P. falciparum strain NF54 and
Anopheles stephensi mosquitoes [17, 18]. The SMFA also
forms the gold standard assay to assess naturally ac-
quired transmission-reducing immunity [18]. Anopheles
stephensi is a primary malaria vector in the Indian sub-
continent but not in Africa where A. funestus and An.
gambiae (s.l.) dominate [19]. Anopheles stephensi and
An. gambiae mosquitoes belong to the subgenus Cellia,
a group of major Old World malaria vectors with a wide
geographical distribution that diversified millions of
years ago [20]. There are several factors in mosquito
physiology and immunity that may contribute to differ-
ences in the vectorial competence of An. stephensi and
An. gambiae [21–24]. These potential differences raise
questions about the extent to which SMFA results, com-
monly using An. stephensi, can be directly translated to
An. gambiae. Here, we compared An. stephensi and An.
gambiae in terms of transmission efficiency and TRA es-
timates in the SMFA using transmission-blocking mAb
and sera of naturally gametocyte-exposed individuals.
Methods
Mosquito rearing, parasite culture and standard
membrane feeding assay
Anopheles stephensi (Sind-Kasur Nijmegen strain) [25]
and An. gambiae (s.s.) (Ngousso strain) [26] were reared
at 30 °C and 70–80% humidity, and exposed to a 12/
12 h day/night cycle. Mature P. falciparum (NF54) ga-
metocytes (14 day culture, 0.3–0.5% gametocytes, 2%
haematocrit) were obtained from an automated tipper
system and prepared as previously described [27, 28].
For infection experiments, 3–5 day-old mosquitoes were
fed on a glass membrane feeder system containing
270 μl of P. falciparum culture mixture [28]. Unfed and
partially fed mosquitoes were removed from the sam-
ples. Blood-fed mosquitoes were maintained at 26 °C
and 70–80% humidity. Routine dissection and staining
of midguts was done 6–9 days post-infection in 1% mer-
curochrome solution for oocysts quantification.
Antibody preparations
Monoclonal antibodies
Four monoclonal antibodies against two P. falciparum
antigens were selected for the SMFA species compari-
son. Rat mAb 85RF45.1 and 85RF45.5, against pre-
fertilization protein Pfs48/45 epitopes 1 and 5, respect-
ively [29] and rat mAb 32F81 [30] and mouse mAb 4B7
against [31] post-fertilization protein Pfs25. Concentra-
tions of mAb were chosen to achieve full and partial
TRA in An. stephensi. All mAb were diluted in human
serum aiming for a final concentration in the feeder for
Pfs48/45-85RF45.1: 10, 2.5, 0.63 and 0.16 μg/ml; Pfs48/
45-85RF45.5: 60, 20, 6.7 and 2.2 μg/ml; Pfs25-4B7: 94,
23.5, 5.9 and 1.47 μg/ml; Pfs25-32F81: 15, 10, 5, 2.5,
1.67, 1.25, 0.63 and 0.56 μg/ml. Human serum was used
as a control for TRA assessments. In the models that
assessed the association between antibody concentration
and TRA, we also included other experiments conducted
with the same mAb in the same lab in the period 1998–
2015 with additional antibody concentrations for Pfs48/
45-85RF45.1 (20–0.04 μg/ml), Pfs48/45-85RF45.5 (100–
6.25 μg/ml) and Pfs25-32F81 (20–0.63 μg/ml).
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Human test sera
Two sets of plasma samples were selected for analysis in
the SMFA species comparison. One set (n = 5) comprised
plasma samples from European expatriates who lived in
malaria endemic regions for more than 10 years, and
showed strong and consistent TRA in the SMFA [18, 32].
A second set (n = 21) comprised plasma samples derived
from gametocyte carriers living in endemic regions in
Cameroon (Yaoundé, 2010–2012) and Burkina Faso
(Bobo-Dioulasso, 2012). Samples were collected for ex vivo
infectivity assessments as reported previously [33]. Ethical
approval was obtained from the Centre Muraz Institutional
Ethics Committee under agreement number 0003–2009/
CE-CM. The protocol conforms to the declaration of
Helsinki on ethical principles for medical research involv-
ing human subjects (version 2002) and informed written
consent were obtained from all volunteers.
IgG was purified from 300 μl plasma samples using
Protein G HP Spintrap (GE Healthcare, Chicago, IL, US)
according to the manufacturer’s instructions and as pre-
viously described [18, 34] and reconstituted in 300 μl of
milliQ water. Yield was 70–80% and IgG concentrations
were 7–18 mg/ml measured with the NanoDrop ND-
1000 (Thermo Scientific, Waltham, MD, US). IgG was
tested by mixing 90 μl of plasma IgG in freeze-dried
foetal calf serum (FCS) (original volume was 90 μl) and
added to 180 μl of gametocyte/red blood cell mix (con-
taining 30 μl of active complement containing serum) to
a total volume of 270 μl. Primary control samples were
90 μl of freeze-dried FCS dissolved in 90 μl milliQ water.
Subsidiary controls (IgG without TRA from an expatri-
ate and individuals from Cameroon and Burkina Faso)
were also tested. In addition, 30 μl of active comple-
ment containing human serum (Sanquin Blood Sup-
ply, Nijmegen, Netherlands) was included in the
culture mix for all serum IgG experiments. No signifi-
cant differences were observed between IgG and FCS
controls. Human IgG controls and FCS were used as
the primary controls as they were available for all ex-
periments. All SMFAs were blinded for evaluation
and analysis.
Statistical analysis
For our analysis we only included experiments with a
minimum of 20 dissected mosquitoes per group and a
minimum infection prevalence of 70% in the control
serum/IgG group (excluded experiments available in
Additional file 1: Table S1) [32]. Statistical analyses were
performed using R software (v 3.2 [35])) and R package
glmmADMB (v 11.6, [36]). TRA was estimated as the
relative reduction in oocyst intensity in the treatment
relative to the control. First, Spearman's correlation tests
were performed on TRA results for both species to
determine whether use of one species over another
would influence candidate prioritization. Subsequently,
generalized linear mixed models (GLMMs) were used to
assess the potential species effect on absolute TRA, as-
suming a zero-inflated negative binomial distribution for
oocysts counts. For each antibody type, treatment, anti-
body concentration and mosquito species were tested as
fixed effects whilst replicate feeds were included as a
random effect to correct for variance between feedings
[37]. Estimates of TBA as the relative reduction in oo-
cyst prevalence (using GLMMs with a binomial distribu-
tion) are presented in Additional file 1: Table S1,
Additional file 2: Figure S1, Additional file 3: Figure S2
and Additional file 4: Figure S3. Intervention TBA has
been shown to vary according to the level of parasitemia
in the mosquito population (as assessed by mean oocyst
intensity in control mosquitoes) [37, 38]. Since the over-
all number of oocysts might vary between mosquito spe-
cies, TRA is used for the comparison between mosquito
species in the main text. All statistics were carried out
on the complete dataset though the figures and TRA es-
timates were obtained by using independent GLMMs for
each individual antibody. To aid visual clarity, experi-
ments where oocyst intensities were higher in test mos-
quitoes than controls were given an efficacy of zero in
the figures but were left unaltered in the statistical
analyses.
Results
The mean oocyst intensity and the prevalence of mos-
quitoes infected with oocysts in An. gambiae and An.
stephensi that were fed the same blood meal without any
interventions were directly compared (Fig. 1a, b). Mean
oocyst intensities in control feeds ranged from 2.9 to
113.7 in An. stephensi (oocyst prevalence 70–100%) and
4.4 to 80.1 for An. gambiae (oocyst prevalence 80–100%).
There was a broad correlation across the whole dataset
between oocyst intensities in An. gambiae and An. ste-
phensi (Spearman's correlation coefficient r = 0.92, 95%
confidence interval (CI): 0.71–0.98, P < 0.0001). Absolute
average numbers of oocysts were not significantly different
between An. gambiae and An. stephensi in control groups;
25.32 (95% CI: 15.13–34.27) oocysts/mosquitoes for An.
stephensi vs 22.77 (95% CI: 19.67–32.58) oocysts/mosqui-
toes for An. gambiae (GLM, z(nb. of observations = 2194) = 1.13,
P = 0.18. The absolute prevalence of oocysts in An. ste-
phensi (83.79%; 95% CI: 59.27–83.81) was statistically sig-
nificantly higher than in An. gambiae (73.26%; 95% CI:
64.33–93.84; z(2194) = 2.55, P = 0.01).
The shape of the relationship between oocyst preva-
lence and oocyst intensity was tested in a larger dataset
where the two mosquito species were not fed on the
same blood sources. This comprises all SMFA experi-
ments conducted between January 2011 and January
2013. The shape of the relationship between prevalence
Eldering et al. Parasites & Vectors  (2017) 10:489 Page 3 of 10
and intensity was similar for both species (Fig. 1c), sug-
gesting the distribution of oocysts across mosquitoes is
the same within An. gambiae and An. stephensi.
Assessments of transmission-reducing activity of
monoclonal antibodies
TRA of four monoclonal antibodies, targeting Pfs48/45
(mAb 85RF45.1 and mAb 85RF45.5) and Pfs25 (mAb
32F81 and mAb 4B7) was investigated using An. stephensi
and An. gambiae. In experiments performed in both spe-
cies, there was a very strong correlation between SMFA
estimates using An. stephensi and An. gambiae (Spear-
man's correlation coefficient r = 0.80, 95% CI: 0.65–0.89%,
P < 0.0001). If experiments were ranked in order of mag-
nitude of TRA, the two species did not rank all experi-
ments in the same order. Six mAb concentrations
combinations resulted in > 80% TRA in An. stephensi
(mAb 85RF45.1 at 10 and 2.5 μg/ml; mAb 32F81 at 15, 10
and 5 μg/ml; mAb 4B7 at 94 μg/ml); 4 of these also
showed > 80% TRA in An. gambiae (mAb 85RF45.1 at 10
and 2.5 μg/ml; mAb 32F81 at 15 and 10 μg/ml) (Fig. 2).
All highly active mAb concentrations tested in our labora-
tory colony of An. gambiae also showed high efficacy in
An. stephensi. For anti-Pfs25 antibody concentrations with
intermediate TRA, the efficacy was sometimes slightly
overestimated in An. stephensi. Similar patterns were seen
between species for transmission-blocking activity (TBA),
showing no significant difference for all mAbs (mAb
85RF45.1, z(2133) = 0.67, P = 0.50; mAb 85RF45.5,
z(2969) = -0.45, P = 0.65; mAb 4B7, z(1070) = -0.93, P = 0.35;
mAb 32F81, z(2594) = -1.66 P = 0.096) (Additional files 2:
Figure S1, Additional file 3: Figure S2). However, variance
in TBA estimates was greater than TRA estimates since
TBA is heavily dependent on control oocysts intensity [37,
38]. Control oocyst intensities vary considerably between
experiments and, although this does not affect the validity
of TRA estimates, high control oocyst intensities
Fig. 2 The ranking of estimates of TRA of antibodies against Pfs48/45
(mAb 85RF45.1 and mAb 85RF45.5) and Pfs25 (mAb 32F81 and mAb
4B7) in An. gambiae and An. stephensi mosquitoes. TRA of transmission
effective mAb 85RF45.1 (blue), 85RF45.5 (red), 32F81 (green) and 4B7
(black) in An. gambiae depending on TRA in An. stephensi mosquitoes.
Dots and triangles represent the predicted TRA, while lines represent
95% confidence intervals in An. gambiae and An. stephensi
Fig. 1 Prevalence and oocyst intensity in An. stephensi and An. gambiae mosquitoes. a Mean oocysts intensity (dots) with 95% confidence intervals (lines)
in An. gambiae depending on mean oocyst intensity with 95% confidence intervals for An. stephensi, for control groups (grey), mAb Pfs48/45-85RF45.1
(blue), mAb Pfs48/45-85RF45.5 (red), mAb Pfs25-32F81 (green) and mAb Pfs25-4B7 (black). b Mean prevalence in oocysts (dots) with 95% confidence
intervals (lines) in An. gambiae depending on mean prevalence with 95% confidence intervals for An. stephensi. Same color codes as for panel
a. c Relationship between oocysts prevalence and intensity for An. stephensi (blue) and An. gambiae (green). The line and shaded area represent
the predicted relationship and predicted confidence interval. Each data point represents the mean oocyst intensity and oocyst prevalence in a
single group of mosquitoes. The size of each data point represents the size of the mosquito group analyzed. Data were collected from both
control and experimental feeds between 6 and 9 days post infection. In total 1635 separate feedings comprising 25,574 mosquito dissections
are shown: 150 feeds with An. gambiae (green) comprising 2691 mosquitoes and 1485 feeds with An. stephensi (blue) comprising
22,883 mosquitoes
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frequently lead to situations where oocyst prevalence is
100% and a considerable reduction in oocyst density is re-
quired before oocyst prevalence is affected, making TBA
as outcome measure less relevant. For our experimental
approach, TRA estimates were therefore considered more
robust and more relevant than TBA estimates.
Although TRA outcomes of different mAb concentra-
tions were ranked in broadly the same order, the actual
TRA estimates showed some differences between An.
gambiae and An. stephensi, demonstrated by a signifi-
cant interaction term between intervention and mos-
quito species using GLMM analysis (z(8766) = -2.71,
P = 0.0067). The difference between mosquito species
varied between antibody type and the efficacy of the
intervention. To illustrate this, the impact of varying ti-
ters on TRA was assessed separately for the different
antibodies.
The highly potent mAb 85RF45.1 showed high levels
of TRA in both mosquito species. At a concentration of
10 μg/ml, the number of oocysts was reduced by 99.8%
(95% CI: 99.5–99.9%) and 99.9% (95% CI: 99.56–99.98%)
in An. stephensi and An. gambiae, respectively (Fig. 3a).
At a concentration of 2.5 μg/ml near complete blockade
was also observed for both species [An. stephensi: 96.2%
(95% CI: 94.3–97.4); An. gambiae: 96% (95% CI: 93.5–
97.5)] while more variable levels of TRA were observed
at lower concentrations. For mAb 85RF45.1, there was
no significant effect of mosquito species on TRA and on
the association between mAb concentration and TRA
(z(2133) = -0.45, P = 0.65 and z(2133) = -1.66, P = 0.10,
respectively).
mAb 85RF45.5 is a much less potent mAb against
Pfs48/45 [29] and at none of the tested concentrations
was TRA consistently above the arbitrary threshold of
80% for reproducible SMFA experiments [39]. TRA esti-
mates for 85RF45.5 were similar between An. stephensi
and An. gambiae mosquitoes (Fig. 3b) and there was no
significant effect of mosquito species on TRA and on
the association between mAb concentration and TRA
(z(2969) = 0.87, P = 0.38 and z(2969) = -0.59, P = 0.55,
respectively).
For mAb 32F81 against Pfs25 we found high TRA activity
in both mosquitoes species at concentrations of 15 μg/ml
[An. stephensi: 91.2% (95% CI: 87.3–93.8) TRA; An. gam-
biae: 82.8% (95% CI: 66.6–91.1)] and 10 μg/ml [An. ste-
phensi: 89.6% (95% CI: 80.1–94.4); An. gambiae: 82.5%
(95% CI: 6.0–96.8) TRA]. Below 10 μg/ml, TRA activity
remained relatively high in An. stephensi [5 μg/ml: 85.8%
(95% CI: 74.0–92.2); 2.5 μg/ml: 76.3% (95% CI: 50.4–88.7)]
but dropped below statistically significant levels in An. gam-
biae (Fig. 3c). The same pattern was observed for antibody
mAb 4B7 against Pfs25: we found high TRA in both mos-
quitoes species at concentrations of 94 μg/ml [An. ste-
phensi: 92% (95% CI: 86.4–95.3), An. gambiae: 67% (95%
CI: 52.8–77.0)]. Below this concentration, TRA remained
relatively high in An. stephensi [23.5 μg/ml: 78.4% (95% CI:
67.7–85.6); 5.9 μg/ml: 49.6% (95% CI: 25.3–66.0)] but
dropped in An. gambiae [23.5 μg/ml: 44.7% (95% CI:
16.1–63.6%); 5.9 μg/ml: below significant levels]
(Fig. 3d). Anopheles stephensi supported a significantly
higher TRA than An. gambiae for both anti-Pfs25
mAb (32F81, z(2594) = -3.95, P < 0.0001; 4B7,
z(1070) = -4.68,P < 0.0001). This difference was signifi-
cantly reduced by increasing antibody concentration
in 4B7 (z(1070) = -4.21, P < 0.0001).
Independent experiments were conducted at the La-
boratory of Malaria and Vector Research (LMVR) using
a very similar SMFA protocol [17] and provide data that
support the above findings. In those experiments three
mouse monoclonal antibodies (3E12, anti-Pfs48/45
mAb; 1B3, anti-Pfs230 mAb; 4B7, anti-Pfs25 mAb) were
tested by SMFA; no difference was observed in TRA be-
tween the two mosquito species for anti-Pfs48/45 and
anti-Pfs230 antibodies whilst TRA estimates were higher
in An. stephensi for anti-Pfs25 mAb (Additional file 5:
Figure S4).
Assessments of transmission-reducing activity of human
serum IgG
Twenty-six human serum samples were selected and
tested in direct paired experiments with the same para-
site material and feeders from the same feeder chain
used for An. stephensi and An. gambiae. Four of 5 sam-
ples from expatriates showed ≥ 99% TRA; the other
sample showing negligible activity in the SMFA. Serum
from one gametocyte carrier from Cameroon and 4 from
Burkina Faso showed high and reproducible levels of
TRA (84–100%). All other field samples showed inter-
mediate to low levels of TRA (Additional file 6: Table
S2). There was a very strong association between SMFA
estimates using An. stephensi and An. gambiae (Spear-
man's correlation coefficient r = 0.85, 95% CI: 0.71–0.93,
P < 0.0001; Fig. 4).
Overall, TRA was significantly higher in An. stephensi
than in An. gambiae mosquitoes (as expressed by the inter-
action term between species and intervention, GLMM
P < 0.01) but with an average difference of only 12.8% (95%
CI:16.2–19.9%). As was seen in the previous analyses the
greatest difference was observed at lower TRA estimates,
with sera giving > 80% TRA being highly comparable in
this experiment (Fig. 4). TBA estimates also showed a good
correlation, and no significant difference, between An. ste-
phensi and An. gambiae (Additional file 4: Figure S3).
Discussion
We compared TRA estimates of antibodies obtained in
the SMFA using the commonly used An. stephensi and
the important African malaria vector An. gambiae. There
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was a strong correlation in TRA efficacy estimates gener-
ated using the two mosquito species. For pre-fertilization
anti-Pfs48/45 monoclonal antibodies and for the highest
concentrations of post-fertilization anti-Pfs25 antibodies
tested here, we found no differences in absolute TRA esti-
mates between the mosquito species. When partially ef-
fective concentrations of antibodies against Pfs25 were
used, we observed higher TRA estimates for An. stephensi.
Anopheles stephensi is commonly used as mosquito vec-
tor in the SMFA as well-established colonies are highly
permissive and allow high oocyst and sporozoite densities
to be achieved [17, 28]. Several characteristics of An. ste-
phensi make this species markedly different from vectors
that play a prominent role in the natural transmission of
P. falciparum in Africa. An. gambiae has a potent
thioester-containing protein-1 (TEP1) dependent immune
Fig. 3 TRA of antibodies against Pfs48/45 (mAb 85RF45.1 and mAb 85RF45.5) and Pfs25 (mAb 32F81 and mAb 4B7) in An. gambiae and An. stephensi
mosquitoes. Figures show the estimates of TRA as relative reduction in oocyst intensity for each experiment (dots for An. gambiae experiments, triangles
for An. stephensi experiments) and the GLMM model predictions and confidence intervals (lines and shaded areas). TRA of mAb in An. gambiae is shown
in green and for An. stephensi it is shown in blue. a Relation between An. gambiae and An. stephensi for TRA of mAb 85RF45.1. b Relation between An.
gambiae and An. stephensi for TRA of mAb 85RF45.5. c Relation between An. gambiae and An. stephensi for TRA of mAb 32F81. d Relation between An.
gambiae and An. stephensi for TRA of mAb 4B7. All TRA calculations were made using human serum controls
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system that is effective against Plasmodium infection. In
our An. gambiae colony silencing TEP1 results in mark-
edly higher infection rates with several P. falciparum
strains [40]. The TEP1 response is absent or at least mark-
edly lower in An. stephensi [24, 41]. The difference in the
interaction between Plasmodium and different anophe-
lines is illustrated by the Plasmodium Pfs47 gene that is
essential to avoid TEP-1 mediated killing in An. gambiae
but plays no evident role in sporogonic development in
An. stephensi [18, 41]. In addition, expression profiles of
proteolytic enzymes during digestion of the blood meal
vary between An. stephensi and An. gambiae mosquitoes
[42, 43], which may affect parasite survival and infectivity.
The composition of bacterial midgut flora can also vary
between mosquito species and may further influence the
efficiency of Plasmodium transmission [44–48] although
this may be less important in our mosquito colonies that
were both maintained in the same laboratory.
Despite these differences, our findings provide no evi-
dence for considerable differences between An. stephensi
and An. gambiae in assessing TRA for pre-fertilization
antibodies, reflected by indistinguishable TRA estimates
for mAb against Pfs48/45 and highly similar TRA esti-
mates for IgG from sera of naturally exposed individuals
where antibodies are exclusively expected against pre-
fertilization antigens [9]. Similarly, the highest concen-
trations of mAb against the post-fertilization antigen
Pfs25 used in our experiments, effectively reduce trans-
mission in both An. stephensi and An. gambiae. Our
findings are less conclusive for lower, partially effective,
concentrations of two different sources of anti-Pfs25
mAb where TRA estimates appeared significantly higher
for An. stephensi. Pfs25 is translationally repressed in ga-
metocytes and expressed in zygote and ookinete stages
where it facilitates midgut invasion [49, 50]. A previous
study reported that Pfs25 specific IgG antibodies from
immunized mice had comparable TRA efficacy in An.
gambiae and An. stephensi mosquitoes based on median
number of oocysts but, similar to our findings, the low-
est IgG concentration resulted in higher infection rates
in An. gambiae. [51]. Whilst independent experiments in
a different laboratory confirmed statistically significant
higher estimate of TRA in An. stephensi compared to
An. gambiae for the post-fertilization antibody Pfs25
4B7 (Additional file 5: Figure S4), further work should
elucidate whether this difference between mosquito spe-
cies is also apparent for other post-fertilization anti-
bodies and whether this reflects differences in antibody
effectiveness that may need to be sustained for > 20 h in
the mosquito gut to prevent further sporogonic develop-
ment after ookinetes have formed [13, 52].
We designed our experiments to test TRA using reduc-
tions in oocyst density as the primary outcome measure. Ul-
timately, oocyst prevalence or the proportion of infected
mosquitoes is a more relevant outcome to predict the com-
munity impact of interventions [5], an impact that may only
become apparent after multiple transmission cycles [53]. Re-
ductions in oocyst intensity (TRA) are typically less
dependent on the efficiency of transmission and are strongly
associated with reductions in oocyst prevalence (TBA) [37].
Our approach thus describes a suitable first step in candi-
date prioritization where multiple concentrations of
transmission-blocking compounds are tested repeatedly
using informative oocyst exposure in a highly permissive
mosquito vector. However, compounds with activities down-
stream of gametocyte development might require testing in
different species combinations to confirm potency in a range
of epidemiologically relevant mosquito species. Our findings
suggest that the SMFA with An. stephensi is an appropriate
system for an important initial screen for TRA of
transmission-blocking compounds. Ultimately, lead candi-
dates will require testing at a range of oocyst intensities [5,
37] and ideally against multiple parasite strains. Testing can-
didates in feeding experiments with lower parasite exposure
than routinely used in the SMFA (i.e. lower oocyst preva-
lence and intensity in control mosquitoes) will be of particu-
lar relevance for partially effective interventions that may
still have a considerable impact on transmission [53]. Since
the SMFA will always fall short of the natural situation of
malaria transmission, testing interventions in the direct
membrane feeding assays (DMFA) using gametocyte carriers
with naturally circulating gametocyte isolates at natural
densities and local mosquito species may provide additional
information [54] that will help bridge the gap between in
Fig. 4 TRA of human serum IgG from Cameroon and Burkina Faso and
serum IgG from Dutch expatriate donor SP in An. gambiae and An.
stephensi mosquitoes. All TRA calculations were made using FCS controls.
TRA calculated using mean oocyst intensity assessments from oocyst
intensity data from feeds with human serum IgG. R was calculated based
on deviation from a perfect linear association (x = y)
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vitro candidate prioritization and predicting the efficacy of
candidate interventions in real life.
Conclusions
Our study shows that monoclonal antibodies of target vac-
cines have comparable levels of transmission reduction in
Anopheles stephensi and Anopheles gambiae mosquitoes.
In addition, human serum IgG sample also have compar-
able levels of transmission reduction in An. stephensi and
An. gambiae mosquitoes. These finding support the use of
An. stephensi in the SMFA for target prioritization. How-
ever, compounds with activities downstream of gameto-
cyte development may require additional testing in
different species combinations to confirm potency in a
range of epidemiologically relevant mosquito species.
Additional files
Additional file 1: Table S1. TRA and TBA estimates of human serum
IgG samples. IgG concentration is shown in mg/ml. TRA estimates are
shown as % reduction in oocyst intensity with 95% CI and TBA estimates
are shown as % reduction in oocyst prevalence with 95% CI. (XLSX 31 kb)
Additional file 2: Figure S1. The ranking of estimates of TBA of
antibodies against Pfs48/45 (mAb 85RF45.1 and mAb 85RF45.5) and Pfs25
(mAb 32F81 and mAb 4B7) in An. gambiae and An. stephensi mosquitoes.
TBA of transmission effective mAb 85RF45.1 (blue), mAb 85RF45.5 (red),
mAb 32F81 (green) and mAb 4B7 (black) in An. gambiae depending on
TBA in An. stephensi mosquitoes. Dots and triangles represent the
predicted TBA, while lines represent 95% confidence intervals in An.
gambiae and An. stephensi. (TIFF 1302 kb)
Additional file 3: Figure S2. TBA of antibodies against Pfs48/45 (mAb
85RF45.1 and mAb 85RF45.5) and Pfs25 (mAb 32F81 and mAb 4B7) in An.
gambiae and An. stephensi mosquitoes. Figures show the estimates of
TBA as relative reduction in oocyst prevalence for each experiment (dots
for An. gambiae experiments, triangles for An. stephensi experiments) and
the GLMM model predictions and confidence intervals (lines and shaded
areas). TBA of mAb in An. gambiae is shown in green and for An. stephensi it
is shown in blue. A Relation between An. gambiae and An. stephensi for TBA
of mAb 85RF45.1 B Relation between An. gambiae and An. stephensi for TBA
of mAb 85RF45.5 C Relation between An. gambiae and An. stephensi for TBA
of mAb 32F81. D Relation between An. gambiae and An. stephensi for TBA of
mAb 4B7. All TRA calculations were made using human serum controls.
(TIFF 4772 kb)
Additional file 4: Figure S3. Correlation between ranking of TBA of
human IgG samples in An. stephensi and An. gambiae. TBA of human
serum IgG in An. gambiae depending on TBA in An. stephensi mosquitoes.
Dots represent the predicted TBA, while lines represent 95% confidence
intervals in An. gambiae and An. stephensi. (TIFF 1082 kb)
Additional file 5: Figure S4. Outcomes of independently conducted
experiments with mouse monoclonal antibodies against Pfs48/45 (mAb
3E12), Pfs230 (mAb 1B3) and Pfs25 (mAb 4B7). Presented are estimates of
transmission reducing activity in An. stephensi (blue) and An. gambiae
(red). Box plots indicate median TRA with quartiles and range. The n
indicates the number of experiments. P-values are for the comparisons
between mosquito species. (TIFF 1206 kb)
Additional file 6: Table S2. Overview of excluded SMFA experiments.
Controls in experiments where prevalence was < 70% are highlighted in
red. (TIFF 262 kb)
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